Previous 10 | Next 10 |
Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...
Corcept Therapeutics (CORT) announces enrollment of the first patient in the Phase 1b trial of relacorilant in combination with Merck's blockbuster cancer drug Keytruda in certain patients with adrenal cancer.The open-label, Phase 1b trial has a planned enrollment of 20 patients wit...
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today a...
Corcept effectively resolved its patent problems with Korlym by winning a ruling against Teva. That paves the way for relacorilant, a next generation drug. The company has cash and Phase 3 data readouts in the next few months. For further details see: Corcept Stock: Majo...
KPTI has fallen 30% on earnings. COVID-19 and some increasing competition have caused lackluster growth. However, the pipeline potential does not justify a sub-$1 billion valuation. For further details see: Karyopharm Stock: Rationale For Bullishness
Corcept Therapeutics (CORT) announces that it has appointed Atabak Mokari as the company's as Chief Financial Officer.Charles Robb, who has been Corcept’s CFO since September 2011, has assumed the role of Chief Business Officer, the company said.Atabak Mokari has ne...
MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone corti...
Corcept Therapeutics (CORT): Q4 Non-GAAP EPS of $0.27 beats by $0.06; GAAP EPS of $0.20 misses by $0.02.Revenue of $85.7M (-2.5% Y/Y) misses by $6.1M.Press Release For further details see: Corcept Therapeutics EPS beats by $0.06, misses on revenue
2020 revenue of $353.9 million, compared to $306.5 million in 2019 Fourth quarter revenue of $85.7 million, compared to $87.9 million in 2019 2020 GAAP net income of $106.0 million, compared to $94.2 million in 2019 Fourth quarter GAAP ne...
Image source: The Motley Fool. Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 Earnings Call Feb 8, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings ...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quar...
Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial o...
A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...